Athersys, Inc. - Common Stock (NQ:ATHX)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 17, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Athersys, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales ↗

February 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News ↗

January 31, 2022

The broader market weakness pervaded into the biotech sector in the week ending Jan. 28, sending stocks lower.

Via Benzinga

Athersys to Host a Virtual Presentation on Its MultiStem® Programs

January 26, 2022

From Athersys, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 21, 2022

Gainers Idera Pharmaceuticals (NASDAQ:IDRA) stock rose 13.0% to $0.71 during Friday's pre-market session. The market value of their outstanding shares is at $37.7...

Via Benzinga

Athersys Appoints Experienced Commercial Leader, Daniel A. Camardo, to Chief Executive Officer

January 20, 2022

From Athersys, Inc.

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 20, 2022

Gainers TCR2 Therapeutics (NASDAQ:TCRR) s...

Via Benzinga

Alzheimer’s Disease Expected to Triple by 2050 While the Development Process for Potential Drug Candidates Increases

January 05, 2022

Palm Beach, FL – January 5, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is the most common reason of progressive dementia in the elderly population. There has been an...

Via FinancialNewsMedia

Topics Death

Athersys Shares Jump After MultiStem Cell Therapy Data Published In Medical Journal ↗

November 30, 2021

Athersys Inc (NASDAQ: ATHX) announced that a manuscript reporting data from its MUST-ARDS clinical trial have been published in the peer-reviewed medical journal,...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

November 30, 2021

Good morning, investor! We're starting off Tuesday with a breakdown of the biggest pre-market stock movers you need to know about!

Via InvestorPlace

Report of Placebo-Controlled Clinical Trial Evaluating MultiStem® Cell Therapy for Acute Respiratory Distress Syndrome Published in Intensive Care Medicine

November 30, 2021

From Athersys, Inc.

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

November 22, 2021

Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 95.32% to $9.61 during Monday's regular session. Trading volume for iSpecimen's stock is 70.9 million as of...

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 19, 2021

Gainers CASI Pharmaceuticals (NASDAQ:CASI

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 19, 2021

Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares...

Via Benzinga

Athersys (ATHX) Q3 2021 Earnings Call Transcript ↗

November 16, 2021

ATHX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Athersys Reports Third Quarter 2021 Results and Provides Corporate Update

November 15, 2021

From Athersys, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 ↗

November 19, 2021

Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE:

Via Benzinga

The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More ↗

November 14, 2021

Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...

Via Benzinga

The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares ↗

November 12, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday ↗

November 12, 2021

Good morning! We're kicking off the final day of the trading week with an overview of the biggest pre-market stock movers for Monday!

Via InvestorPlace

Athersys Reports Updates on Timing for Japan ARDS and Stroke Programs From Healios K.K.

November 12, 2021

From Athersys

Via Business Wire

Athersys to Host Third Quarter Financial Results Call

October 18, 2021

From Athersys, Inc.

Via Business Wire

The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗

October 06, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (...

Via Benzinga

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO ↗

October 01, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks...

Via Benzinga

Athersys to Present at 2021 Cell & Gene Meeting on the Mesa Hybrid Conference

September 28, 2021

From Athersys, Inc.

Via Business Wire

The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug ↗

September 30, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...

Via Benzinga

August 13, 2021

Via FinancialNewsMedia

Athersys Partner HEALIOS K.K. Completes Enrollment in the TREASURE Study of MultiStem Treatment for Ischemic Stroke

August 10, 2021

From Athersys, Inc.

Via Business Wire

Athersys (ATHX) Q2 2021 Earnings Call Transcript ↗

August 10, 2021

ATHX earnings call for the period ending June 30, 2021.

Via The Motley Fool

Topics Earnings

Athersys: Q2 Earnings Insights ↗

August 09, 2021

Shares of Athersys (NASDAQ:ATHX) increased in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share were unchanged 0.00% over the...

Via Benzinga

Athersys Reports Second Quarter 2021 Results

August 09, 2021

From Athersys, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.